News AZ makes case for hypophosphatasia drug after phase 3 miss AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?
News AstraZeneca cuts ribbon on new R&D facility in Massachusetts AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.
News AZ takes stake in Summit Therapeutics in $2bn deal AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
News FDA starts speedy review of Imfinzi in bladder cancer AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
News AZ's gMG drug Klygefa nears EU approval AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
News NICE finally backs Enhertu for HER2-low breast cancer Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.